Efficacy of second-line dolutegravir- versus boosted protease inhibitor-based ART in children and adolescents living with HIV at 96 and 144 weeks: pooled analysis of the ODYSSEY and CHAPAS-4 trials

17 Jul, 2025

Presented by: Amuge P on behalf of the CHAPAS-4 trial, ODYSSEY trial and UNIVERSAL teams

Presented at: International Workshop on HIV and Pediatrics